title: Role of adiponectin in metabolic and cardiovascular disease.
abstract: Under disease conditions including obesity (insulin resistance) and diabetes, dysregulation of adipokines such as tumor necrosis factor (TNF)-α, leptin, resistin, and adiponectin contribute to the development of metabolic and cardiovascular disease. Unlike other adipokines, adiponectin has been shown to be a therapeutic target for metabolic syndrome and cardiovascular disease. Circulating levels of adiponectin are markedly reduced in obese, diabetic, hypertensive, and coronary artery disease patients as well as experimental animal models of insulin resistance and diabetes. Recently, the small molecule adiponectin receptors (AdipoRs) agonist was discovered and suggested that the agonist is a novel therapeutic target for the treatment of type 2 diabetes linked to obesity in an experimental mouse model. This review will focus on signaling pathways involved in adiponectin and its receptors and the role of adiponectin in metabolic and cardiovascular disease including insulin resistance, cardiomyopathy, and cardiovascular dysfunction.
authors.affiliation: Dalton Cardiovascular Research Center, University of Missouri-Columbia, MO, USA.
authors.forename: Sewon
authors.initials: S
authors.lastname: Lee
authors.affiliation: Department of Kinesiology, Inha University, Incheon, Korea.
authors.forename: Hyo-Bum
authors.initials: HB
authors.lastname: Kwak
keywords: AMPK; AdipoRON; Adiponectin receptors; PPARα